Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug PALI-2108 in adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. This phase 2 study compares different doses of PALI-2108 against a placebo to assess how well the drug works, its safety, and how the body processes it. The study focuses on measuring clinical remission and endoscopic improvement to understand the drugs impact. Participants will receive either 15 mg or 30 mg of PALI-2108 once daily or a matching placebo. The treatment is given orally, and the study uses a randomized, double-blind design where neither participants nor researchers know which treatment is assigned. The study includes induction and maintenance therapy periods, with assessments at 12 weeks and up to 48 weeks to evaluate clinical response and remission. During the study, participants will undergo regular clinical evaluations including the modified Mayo Score assessments, endoscopic examinations, and monitoring for adverse effects. The primary outcome is the proportion of participants achieving clinical remission at Week 12. Secondary outcomes include clinical response and endoscopic improvements at Weeks 12 and 48. Participants safety and drug effects will be closely monitored throughout the study duration, which may last up to about two years from enrollment.
Actively Recruiting
Healthy Volunteer
The American Joint Replacement Registry AJRR is a not-for-profit organization focused on collecting data and improving quality for total hip and knee replacement surgeries across the United States. This observational study collects information to support quality improvement efforts involving hospitals, surgeons, insurers, and device manufacturers. The registry is supported by several professional societies including the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons. Participants are individuals undergoing total joint arthroplasty. Data is collected observationally without specific treatment assignments or interventions. The registry gathers information from various sources to monitor outcomes and quality measures related to joint replacement surgeries. Participants health-related quality of life will be assessed at 12 months, along with specific measures like the Hip disability and Osteoarthritis Outcome Score - Joint Replacement HOOS, JR. The study collects ongoing data to support improvements in joint replacement care while allowing participants to continue with their usual medical care. Participation duration varies depending on individual surgery and follow-up schedules.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.
Actively Recruiting
Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.
Actively Recruiting
Researchers are evaluating the Arthrex LoopLocTM device to see if it provides better capsular closure during hip arthroscopy compared to other treatments. The hip capsule is the tissue surrounding the hip joint that supports and stabilizes it, and it must be cut during hip arthroscopy. Traditional repair methods use knotted sutures that may cause irritation and scar tissue, potentially leading to pain. This study aims to compare outcomes between patients who receive the LoopLocTM device and those who do not after primary hip arthroscopy. Participants will either have the LoopLocTM device used for capsular closure during their hip arthroscopy or will undergo the procedure without this device as part of a control group. This prospective, multi-center study involves following patients for two years after surgery. Researchers will collect patient-reported and clinical outcomes to evaluate the feasibility and benefits of the knotless LoopLocTM device. During the two-year follow-up, patients will regularly visit their providers and researchers to assess outcomes such as the Modified Harris Hip Score, Non-Arthritic Hip Score, International Hip Outcome Tool, Hip Outcome Score Sports-Specific Subscale, Visual Analog Scale, and patient satisfaction. The study will monitor and compare these measures to determine if using the LoopLocTM device leads to improved results after hip arthroscopy.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of LY4268989 combined with mirikizumab compared to mirikizumab alone in adults with moderately to severely active ulcerative colitis UC. This Phase 2, randomized, double-blind study focuses on treatment for UC, aiming to determine whether the combination improves clinical remission and response rates. Participants will receive either LY4268989 orally along with mirikizumab administered first intravenously then subcutaneously, or mirikizumab with a placebo oral treatment. Responders during the study will be re-randomized for a second study period. Treatment lasts approximately 104 weeks with up to 21 visits. Throughout the study, participants will attend regular visits for assessments including clinical remission status using the modified Mayo Score at weeks 12, 24, and 48, as well as endoscopic improvement and symptomatic remission. Safety and response to treatment will be monitored over about 118 weeks of total participation.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study involves participants aged 18 to 80 who have had UC for at least three months and have active symptoms confirmed by specific scoring methods. This Phase 2 clinical trial is sponsored by Eli Lilly and Company and focuses on treatment effects over a long period. Participants will receive oral doses of LY4268989 or a matching placebo in a randomized, double-blind design. The study includes two experimental dose groups of LY4268989 and one placebo group. Treatment and evaluation will continue for up to approximately 108 weeks, excluding the screening period. During the trial, participants will be regularly assessed for clinical remission and response using the Modified Mayo Score at weeks 10 and 52. Researchers will monitor symptomatic responses and drug levels in the blood up to week 52. Safety and effectiveness data will be collected throughout the study, with the overall duration lasting up to about two years.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Crohns disease and Ulcerative Colitis are types of inflammatory bowel diseases that cause long-lasting, severe inflammation in the digestive tract. Crohns disease can affect any part of the digestive tract causing symptoms like belly pain, diarrhea, tiredness, and weight loss, while Ulcerative Colitis affects the lining of the rectum and colon causing bleeding, belly pain, and diarrhea. This Phase 2 platform basket study is evaluating the safety and effectiveness of advanced therapies in adults with moderately to severely active Crohns Disease or Ulcerative Colitis. The study includes two substudies focusing on different treatment combinations for participants with Crohns Disease or Ulcerative Colitis. Substudy 1 evaluates the combination of risankizumab and trosunilimab ABBV-466, while Substudy 2 evaluates risankizumab combined with ABBV-701 ABBV-7066. Participants will be randomly assigned first to a substudy and then to a treatment arm within that substudy. Treatments involve induction and maintenance doses of risankizumab, trosunilimab, ABBV-701, or their combinations, given via injection or infusion. Participants will attend regular visits at hospitals or clinics for medical assessments including blood and stool tests, endoscopies, monitoring for side effects, and completing questionnaires and daily diaries. The study measures include the percentage of participants achieving endoscopic remission at Week 28 and the number of participants experiencing adverse events up to 98 weeks. Secondary outcomes include clinical remission and response rates at Weeks 12 and 28. The study will monitor participants for up to 98 weeks from the start of treatment.